Incyte (Nasdaq:INCY) announces the appointment of Susanne Schaffert, Ph.D., as a new member of its Board of Directors.
“On behalf of the Incyte Board of Directors, I am happy to welcome Susanne. Her extensive commercial, development and industry experience will greatly complement our Board and we look forward to Susanne’s contributions to our continued growth and future success,” said Hervé Hoppenot, Chief Executive Officer, Incyte.
“I am very excited for the opportunity to join the Incyte Board of Directors and helping the organization in its commitment to leading scientific innovation and developing new medicines for patients in need. I look forward to being part of this dynamic Company,” said Dr. Schaffert.
For 26 years, Dr. Schaffert served in various global, regional and national roles of increasing responsibilities at Novartis AG including, most recently, as President of Novartis Oncology where she oversaw a very broad portfolio in Solid Tumors and Hematology. Prior to that role, Dr. Schaffert served from 2018 to 2019 as President and Chair of Accelerated Advanced Applications, launching the first radio-ligand therapy in Neuroendocrine tumors, and from 2012 to 2018 as General Manager Region Europe, Novartis Oncology. Prior to those positions, Dr. Schaffert was Global Head of Investor Relations, Global Franchise Head for Immunology and Transplantation and held a series of positions in sales and marketing from the time she joined Novartis Germany in 1995. Dr. Schaffert is also a member of the board of directors of Rubius Therapeutics, Inc.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including risks related to market competition, the results of and risks associated with research and development, risks and uncertainties associated with sales, marketing and distribution requirements, and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its annual report and its quarterly report on Form 10-Q for the quarter ended June 30, 2022. Incyte disclaims any intent or obligation to update these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221004005151/en/